Correct Answer: A. Hormone receptor staining
The Van Nuys Prognostic Index (VNPI) is a validated scoring system specifically designed to stratify risk and guide treatment decisions in ductal carcinoma in situ (DCIS) of the breast. It comprises four independent variables: nuclear grade, presence of comedo-type necrosis, margin width, and patient age at diagnosis. Hormone receptor status (ER/PR positivity) is NOT a component of the VNPI scoring system. While hormone receptor status is prognostically important in invasive breast cancer and influences adjuvant endocrine therapy decisions, it does not factor into DCIS risk stratification per the Van Nuys system. The VNPI was developed to predict the risk of ipsilateral breast tumor recurrence (IBTR) and helps determine whether breast-conserving therapy alone, radiation, or mastectomy is appropriate. In Indian clinical practice, where DCIS diagnosis is increasing with improved screening and imaging, the VNPI remains the standard tool for DCIS management counseling, independent of receptor status.
Why the other options are wrong
B. Presence of microcalcification — Microcalcification is a key component of the VNPI. The presence of comedo-type necrosis (which often manifests as microcalcifications on mammography) is one of the four scoring variables. This is a discriminating feature that directly influences DCIS grade and recurrence risk prediction. C. Size of the tumor — Tumor size is explicitly included in the VNPI as margin width (distance from DCIS to surgical margin). Margins <1 mm, 1–9 mm, and ≥10 mm are scored differently. This is a critical factor determining whether additional radiation or mastectomy is needed in Indian breast cancer centers. D. Age of the patient — Patient age at diagnosis is one of the four core VNPI variables. Younger age (<40 years) is associated with higher recurrence risk and is weighted in the scoring system. This demographic factor is routinely assessed in DCIS counseling in Indian oncology practice.
High-Yield Facts
- Van Nuys Prognostic Index comprises four variables: nuclear grade, comedo necrosis, margin width, and patient age—NOT hormone receptor status.
- VNPI score ranges from 4–12; scores ≤6 predict low recurrence risk suitable for BCT alone, while scores ≥8 suggest mastectomy or BCT + radiation.
- Hormone receptor status in DCIS does NOT influence VNPI scoring but may guide endocrine therapy decisions in selected cases.
- Comedo-type necrosis (manifesting as microcalcifications) is a VNPI component indicating aggressive biology and higher recurrence risk.
- Margin width <1 mm is associated with significantly higher IBTR and is a key VNPI discriminator in Indian breast-conserving therapy decisions.
Mnemonics
VNPI Components (Not ER/PR) Nuclear grade, Comedo necrosis, Margin width, Age — remember: NCMA (or 'No Chemo, Margins & Age'). Hormone receptors are NOT included. DCIS Risk Stratification Memory Hook Think 'DCIS = Grade + Necrosis + Margins + Age' — these four pillars determine recurrence risk. Receptor status is for invasive cancer, not DCIS grading.
NBE Trap
NBE pairs DCIS with hormone receptor testing (which is clinically relevant in invasive breast cancer) to trap students who conflate DCIS prognostication with invasive cancer risk stratification. The VNPI was designed before routine ER/PR testing in DCIS became standard, and receptor status remains outside the formal scoring system.
Clinical Pearl
In Indian breast centers, a VNPI score is calculated at multidisciplinary tumor board to counsel patients on BCT eligibility and radiation need. A 45-year-old with high-grade DCIS, comedo necrosis, and margins <1 mm scores ≥8 and typically requires mastectomy or BCT + adjuvant radiation, regardless of ER/PR status—which would only influence endocrine therapy if invasive recurrence occurs.
_Reference: Bailey & Love's Short Practice of Surgery (Ch. Breast); Robbins Pathology (Ch. Breast Pathology); Harrison Principles of Internal Medicine (Ch. Breast Cancer)_